Transcend Capital Advisors LLC Purchases New Shares in Humana Inc. (NYSE:HUM)

Transcend Capital Advisors LLC purchased a new stake in shares of Humana Inc. (NYSE:HUM) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 1,159 shares of the insurance provider’s stock, valued at approximately $433,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HUM. Rakuten Securities Inc. acquired a new stake in shares of Humana in the fourth quarter valued at about $25,000. Cetera Trust Company N.A acquired a new stake in shares of Humana in the fourth quarter valued at about $28,000. Private Wealth Management Group LLC acquired a new stake in shares of Humana in the fourth quarter valued at about $32,000. Carolinas Wealth Consulting LLC grew its position in shares of Humana by 274.1% in the fourth quarter. Carolinas Wealth Consulting LLC now owns 101 shares of the insurance provider’s stock valued at $46,000 after purchasing an additional 74 shares during the period. Finally, Turtle Creek Wealth Advisors LLC acquired a new stake in shares of Humana in the fourth quarter valued at about $55,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

Humana Trading Up 1.3 %

Shares of Humana stock traded up $4.64 on Friday, reaching $363.62. The company had a trading volume of 1,076,306 shares, compared to its average volume of 1,396,067. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.67 and a current ratio of 1.66. The firm has a market cap of $43.78 billion, a PE ratio of 22.64, a PEG ratio of 2.09 and a beta of 0.51. The firm’s 50 day moving average price is $367.90 and its two-hundred day moving average price is $347.35. Humana Inc. has a 52-week low of $298.61 and a 52-week high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $8.94 earnings per share. Sell-side analysts predict that Humana Inc. will post 16.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on HUM. UBS Group decreased their price target on shares of Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, April 25th. Cantor Fitzgerald reissued a “neutral” rating and issued a $360.00 price target on shares of Humana in a research note on Tuesday, July 23rd. Jefferies Financial Group decreased their price target on shares of Humana from $411.00 to $381.00 and set a “buy” rating on the stock in a research note on Monday, April 22nd. Morgan Stanley began coverage on shares of Humana in a research note on Monday, June 24th. They issued an “equal weight” rating and a $374.00 price target on the stock. Finally, Piper Sandler started coverage on shares of Humana in a research note on Wednesday, June 26th. They issued an “overweight” rating and a $392.00 price target on the stock. Fourteen investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, Humana has an average rating of “Hold” and a consensus target price of $403.55.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.